Table 2.

Effect of Inhibitors on the Expression of Apoptosis and Proliferation Markers in Malignant Human Urothelial Cells

Cell LineMarker0.1% (v/v) DMSO (%)1 μmol/L PD153035 (%)5 μmol/L U0126 (%)5 μmol/L LY294002 (%)20 μmol/L 15dPGJ2 (%)
RT4Cleaved caspase-3<1<1<1<131.3
Cleaved CK18<1<1<1<128.8
Ki6761.260.646.54140.2
RT112Cleaved caspase-3<1<1<1<129.7
Cleaved CK18<1<1<1<132.4
Ki675351.420.533.621.8
EJCleaved caspase-3<1<1<1<144
Cleaved CK18<1<1<1<153.7
Ki6780.162.740.953.539.8
  • NOTE: Immunofluorescence labeling was done on RT4, RT112, and EJ cells after 3-day treatments with 0.1% (v/v) DMSO, 1 μmol/L PD153035, 5 μmol/L U0126, and 5 μmol/L LY294002 or after a 24-h treatment with 20 μmol/L 15dPGJ2. The mean percentage of cells expressing cleaved caspase-3, cleaved CK18, or Ki67 is shown. Each data point is the mean from three replicate fields, and representative results from duplicate experiments are shown. Note the low levels of expression of the markers for apoptosis, except in cells treated with 15dPGJ2, and reduced expression of the proliferation marker after treatment with any of the inhibitors compared with the vehicle-only control.